AMCP: The Academy of Managed Care Pharmacy

Among the most-read coverage for the annual meeting were presentations on the potential and costs of cell and gene therapies, the latest trends in the industry, and pharmacogenomic testing in mental health.

At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.

The FDA granted accelerated approval to talquetamab on August 9, 2023, as a treatment option for adult patients with relapsed/refractory multiple myeloma (RRMM) who have failed at least 4 prior lines of therapy.

Session speakers at the Academy of Managed Care Pharmacy (AMCP) 2024 annual conference share their favorite parts of the event and the key takeaways they will leave the conference with.

A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.

Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.

Leslie Fish, PharmD, senior vice president of pharmacy at IDP Analytics, LLC, reflects on the future of biosimilars and the impact they will have on managed care pharmacy settings to improve patient access to medications.

The Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting included multiple poster presentations featuring studies on atopic dermatitis, 2 of which focused on the impact of ruxolitinib cream monotherapy and educating managed care professionals.

Adam Colborn, JD, director of government relations for the Academy of Managed Care Pharmacy, discussed how providers can comfortably switch patients to biosimilars while minimizing anxieties, as well as the impacts prior authorization requirements can have on patient access.

At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.

Yuqian Liu, PharmD, Magellan Rx Management, explores the current space of cell and gene therapies based on real-world data and potential emerging therapies in the future, while expanding upon long-term efficacy concerns.

Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.

Jenny Craven, PharmD, BCPS, of the University of California Davis Health reviews the finances associated with Emerging Therapy Committee and examines the benefits of the adoption process of new therapies.

Kimberly Westrich, MA, of the National Pharmaceutical Council, addresses the benefits of incorporating patient-centricity throughout the health care system to foster more accurate and better quality of care.

Sarah Bajorek, PharmD, MBA, BCACP, University of California, Davis Health, discusses notable gene therapies emerging into the market and strategies to proactively engage with a wide range of stakeholders during the integration of a new gene therapy.

Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.

Presenters explored the real-world evidence in support of biosimilars at the Academy of Managed Care Pharmacy 2024 annual meeting.

Legal expert in health care, partner, and cochair of the health care coverage and reimbursement practice at Foley Hoag LLP, Ross Margulies discusses his excitement and expectations as a featured speaker at the upcoming 2024 AMCP Annual Conference.

Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, anticipates the 2024 AMCP Annual Conference as an opportunity to engage with fellow managed care pharmacy stakeholders in addressing evolving health policy challenges.

The keynote session highlighted trends in COVID-19 and other respiratory illness rates, a bounce back in health care utilization, biosimilar market trends, new product launches, and more.

Representatives from Magellan Rx Management provided a detailed overview of current treatment options in ophthalmology and the impact that biosimilars could have during a session at AMCP 2023.

Michael Burger, senior consultant at Point-of-Care Partners, explains that real-time benefit check lets physicians know how much a drug will cost the patient at the time they're writing the prescription, allowing them to give the patient a treatment they know they can afford.

In this AMCP Market Insights session, panelists discussed best practices and challenges when it comes to prescribing antibody drug conjugates, from the payer, provider, and patient perspectives, based on survey findings.

Among these treatments is an aflibercept product with improved dosing for the patient that is coming up for approval in a few months, explained Jeffrey Casberg, senior director of pharmacy at IPD Analytics.

The lower number needed to treat suggests that ruxolitinib cream may be more effective for patients with atopic dermatitis (AD), according to a poster presented at AMCP 2023.

Advantages to using surrogate vs clinical end points in drug approvals include earlier access, but there can be concerns about the efficacy and end result of the drug, said Yuqian Liu, PharmD, senior director of specialty clinical solutions at Magellan Rx Management.

Pharmacy benefit manager reform is a major trend in state managed care policy, said Adam Colborn, director of government relations at the Academy of Managed Care Pharmacy (AMCP).

Implementing a strategy that focuses on dose rounding for chemotherapies can have a 3-fold impact of decreasing drug costs, minimizing drug waste, and improving treatment efficiency. This strategy and its benefits were explored in a session on day 2 of AMCP 2023.

In this session at AMCP 2023, speakers broke down the challenges many managed care organizations face when wanting to collect detailed data on health disparities and proffered potential strategies that may help to facilitate gathering these data to address inequitable health care access.

Scott Soefje, PharmD, director of pharmacy cancer care at Mayo Clinic, explains the various ways drug dose rounding can reduce waste, reduce costs, and make drug administration more efficient.